RP101075

RP101075, an active metabolite of Ozanimod, is a potent, orally active S1PR (sphingosine-1-phosphate receptor 1) agonist, with an EC50 of 0.27 nM. RP101075 displays >100-fold selectivity over S1PR5 (EC50=5.9 nM) and >10000-fold over S1PR 2, 3, and 4. RP101075 displays superior cardiovascular safety profile[1].

Product Specifications

CAS Number

[1306760-73-5]

UNSPSC

12352005

Target

Drug Metabolite; LPL Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/rp101075.html

Concentration

10mM

Purity

99.19

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

N#CC1=CC(C2=NC(C3=CC=CC4=C3CC[C@@H]4N)=NO2)=CC=C1OC(C)C

Molecular Formula

C21H20N4O2

Molecular Weight

360.41

References & Citations

[1]Sun N, et al. Selective Sphingosine-1-Phosphate Receptor 1 Modulation Attenuates Experimental Intracerebral Hemorrhage. Stroke. 2016;47 (7) :1899-1906.|[2]Taylor Meadows KR, et al. Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus. PLoS One. 2018;13 (4) :e0193236. Published 2018 Apr 2.